Roche initiated with a Buy at Argus. Argus analyst John Staszak initiated Roche with a Buy rating and a price target of $40, saying that while some of the company’s strong “blockbuster” products are maturing or facing competition from biosimilars, the pipeline of its new programs should support revenues. The analyst is also positive on the company’s focus of tailoring treatments to patients by combining its expertise in pharmaceuticals and diagnostics. Staszak expects the sales momentum of Roche to generate “above-industry-average EPS growth over the next two years,” adding that his implied price target assumes higher valuation multiples and improved earnings.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.